ATE444372T1 - Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren - Google Patents

Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren

Info

Publication number
ATE444372T1
ATE444372T1 AT01939734T AT01939734T ATE444372T1 AT E444372 T1 ATE444372 T1 AT E444372T1 AT 01939734 T AT01939734 T AT 01939734T AT 01939734 T AT01939734 T AT 01939734T AT E444372 T1 ATE444372 T1 AT E444372T1
Authority
AT
Austria
Prior art keywords
vectors
transcomplementation
compositions
gene transfer
efficient gene
Prior art date
Application number
AT01939734T
Other languages
English (en)
Inventor
William J Ramsey
James N Higginbotham
Charles J Link
Original Assignee
Human Gene Therapy Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Gene Therapy Res Inst filed Critical Human Gene Therapy Res Inst
Application granted granted Critical
Publication of ATE444372T1 publication Critical patent/ATE444372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01939734T 2000-05-31 2001-05-31 Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren ATE444372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824800P 2000-05-31 2000-05-31
PCT/US2001/017524 WO2001092550A2 (en) 2000-05-31 2001-05-31 Methods and compositions for efficient gene transfer using transcomplementary vectors

Publications (1)

Publication Number Publication Date
ATE444372T1 true ATE444372T1 (de) 2009-10-15

Family

ID=22773865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939734T ATE444372T1 (de) 2000-05-31 2001-05-31 Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren

Country Status (6)

Country Link
US (2) US7125549B2 (de)
EP (1) EP1287153B1 (de)
AT (1) ATE444372T1 (de)
AU (1) AU2001265219A1 (de)
DE (1) DE60140052D1 (de)
WO (1) WO2001092550A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365260A1 (en) * 2001-10-16 2003-09-02 Genstar Therapeutics Corporation Replication competent dual-ad vectors for vaccine and immunotherapy applications
CN1813067A (zh) * 2003-04-29 2006-08-02 康乃尔研究基金会有限公司 植物光敏素a基因的转基因表达
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
WO2005023313A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv humans
HUE037808T2 (hu) 2006-09-26 2018-09-28 Infectious Disease Res Inst Szintetikus adalékanyagot tartalmazó vakcina kompozíció
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN100593389C (zh) * 2007-07-10 2010-03-10 清华大学 一种连续动态采集式小动物诱发荧光分子成像系统
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP3711768A1 (de) 2013-04-18 2020-09-23 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
CN110964747A (zh) * 2019-11-26 2020-04-07 深圳市人民医院 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL179877B1 (pl) * 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
EP0707071B1 (de) 1994-08-16 2003-07-30 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
DE69733035T2 (de) * 1996-11-19 2005-11-24 University of Alabama, Birmingham Research Foundation, Birmingham Chimäres retrovirus/adenovirus system
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO2000017376A1 (en) * 1998-09-22 2000-03-30 The Governement Of The United States Of America, As Represented By The Secretary Of The Departement Of Health And Human Services Replication deficient retroviral vector system and methods of using
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1059356B1 (de) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer

Also Published As

Publication number Publication date
WO2001092550A2 (en) 2001-12-06
US20020042139A1 (en) 2002-04-11
EP1287153B1 (de) 2009-09-30
US7125549B2 (en) 2006-10-24
EP1287153A2 (de) 2003-03-05
AU2001265219A1 (en) 2001-12-11
WO2001092550A3 (en) 2002-03-28
DE60140052D1 (de) 2009-11-12
US6875610B2 (en) 2005-04-05
US20060216271A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE444372T1 (de) Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
WO2003080807A3 (en) Compositions and methods for suppressing eukaryotic gene expression
NO20065084L (no) Interferon-alfa polypeptider og konjugater
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
SI2012822T1 (sl) Modificirani adenovirusni protein hekson in njegove uporabe
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2008028661A3 (en) Potexvirus- derived replicon
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
WO2007044024A3 (en) Recombinant influenza vectors with tandem transcription units
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
ATE536415T1 (de) Klonierung des cytochrome p450 gens von nicotiana
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
PL374312A1 (en) Endothelial stem cells, populations, methods of isolation and use thereof
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
BR0308634A (pt) Uso de um adenovìrus, e, composição
EP1773363A4 (de) Ngna-zusammensetzungen und anwendungsverfahren
WO2007134325A3 (en) Methods and compositions for protein production using adenoviral vectors
WO2004022782A3 (en) Compositions and methods for tissue specific or inducible inhibition of gene expression
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
IL175558A0 (en) A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
WO2003076583A3 (en) Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
AU2294102A (en) Mutant muscle-specific enhancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties